Svenska
Glossary
Search
Media Releases 2012
Media Archive
Presentations
Image Bank
Calendar
Media Contact
Media Archive
December 6, 2011
NeuroNova concludes a first-in-human study with a novel treatment for patients with Parkinson´s disease
March 10, 2011
NeuroNova founder Professor Jonas Frisén awarded the AkzoNobel Science Award 2011
March 18, 2009
NeuroNova initiates a first-in-human study with a novel treatment for patients with Parkinson´s disease
March 18, 2009
NeuroNova initierar en första patientstudie med en ny behandling av patienter med Parkinsons sjukdom
June 22, 2010
NeuroNova´s drug candidate sNN0029 for ALS/Lou Gehrig´s disease receives orphan drug designation by the FDA
March 11, 2009
NeuroNova concludes a License and Option Agreement with Genentech Inc. for the use of VEGF in the treatment of ALS (Lou Gehrig´s Disease)
Mars 11, 2009
NeuroNova ingår ett licens- och optionsavtal med Genentech Inc. för att utveckla ett biologiskt läkemedel för patienter med ALS
December 1, 2008
NeuroNova initiates a first-in-human study with a potential treatment for patients with ALS
November 11, 2008
NeuroNova receives regulatory approval to initiate the first-in-human study with sNN0031 for patients with Parkinson´s disease.
July 15, 2008
NeuroNova submits a clinical trial application to initiate the first-in-human study with sNN0029 for patients with Amyotrophic Lateral Sclerosis.
Januari 1, 2008
NeuroNova awarded grant to fund clinical trial of Parkinson’s disease treatment
December 21, 2007
NeuroNova submits a clinical trial application to initiate the first-in-human study with sNN0031 for patients with Parkinson´s disease
September 12, 2007
Exendin induces recovery in preclinical model of Parkinson's disease
June 15, 2007
CG Johansson is appointed new Chairman of the Board for NeuroNova
June 5, 2007
U.S. patent, licensed to NeuroNova, issued for the use of VEGF in the treatment of ALS
April 16, 2007
NeuroNova prepares for clinical trials and hires Chief Medical Officer
March 2, 2007
New evidence for neurogenesis in the adult human brain
February, 2007
NeuroNova completes new financing
December 31, 2006
NeuroNova is a partner in EU's StemStroke consortium
December 1, 2005
NeuroNova receives U.S. patent for the use of therapeutics to increase neurogenesis.
November 15, 2005
NeuroNova’s sNN0031 återskapar friskt rörelsemönster och orsakar bildning av nya nervceller i en modell av Parkinsons sjukdom
November 15, 2005
NeuroNova’s sNN0031 restores normal movement and promotes formation of new brain cells in model of Parkinson’s disease
December 01, 2004
NeuroNova Prepares for Next Phase by Appointing New CEO
June 28, 2004
NeuroNova featured on Wall Street Reporter
June 27, 2004
NeuroNova announces changes in its Board of Directors
Stockholm, February 3, 2004
NeuroNova to participate in European Initiative in Stem Cell Research
October 1, 2003
NeuroNova expands and reorganizes Senior Management Team
September 10, 2003
NeuroNova ingår samarbetsavtal med Lundbeck A/S
September 10, 2003
NeuroNova announces collaboration agreement with Lundbeck A/S
September 10, 2003
NeuroNova genomför ny finansieringsrunda
September 10, 2003
NeuroNova completes new round of financing
June 19 2003
NeuroNova as nominee for the 2003 World Technology Awards
June 19 2003
NeuroNova reports issuance of U.S. patent on adult neural stem cells
June 18, 2003
Meet representatives from NeuroNova at the BIO2003 Annual Convention, June 22-25, in Washington DC
October 20, 2002
NeuroNova in TIME Magazine's Digital Top 25 for 2002
May 13, 2002
NeuroNova recognized by Red Herring Editors for Innovation and Business Strategy
December 21, 2001
Connect Sweden Biomedical Partnership Forum 2001 selects NeuroNova for Film presentation
Stockholm, December 21, 2001
NeuroNova obtains rights to method for determining the fate of stem and progenitor cells
June 1, 2000
NeuroNova AB Advances Stem Cell Research with Landmark Discovery Stem Cells in Adult Mouse Brain Have Potential to Generate Cells of Other Organs
March 20, 2000
NeuroNova AB Completes Financing Round of SEK 30 Million
© NeuroNova AB, Sweden, Tel: +46 (0)8 786 0900, Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Sitemap
Site policy
Project Pipeline
Project
Indication
Pre-clin.
IND
Phase I/II
Phase II
Phase III
sNN0029
ALS
sNN0031
Parkinson's disease
More about our Projects
Business Development
NeuroNova’s business strategy centers on developing novel therapeutic products based on neurogenesis in areas of high unmet medical need in neurodegenerative diseases.
More about business development.
